Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
A side-by-side comparison of compounded tirzepatide and brand-name Mounjaro® (Eli Lilly), focused on the type 2 diabetes indication, insurance coverage, and clinical decision-making.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
Side-by-side comparison
Attribute
Compounded tirzepatide
Mounjaro® (brand)
FDA-approved indication
None (not FDA-approved)
Type 2 diabetes
Manufacturer
503A or 503B pharmacy
Eli Lilly
Monthly cash price (full)
$186–$379/mo
~$1,069/mo (cash MSRP)
Insurance coverage
No (cash-pay only)
Broad for T2D; PA often required
Medicare Part D
No
Yes (for T2D)
Form factor
Multi-dose vial
Pre-filled single-dose pen
Quality assurance
USP <71> / USP <85> / HPLC CoA (provider-dependent)
FDA-inspected cGMP
Mounjaro vs Zepbound — same molecule, different labels
Mounjaro and Zepbound are both tirzepatide manufactured by Eli Lilly. The FDA approved Mounjaro for type 2 diabetes first (May 2022); Zepbound was approved for chronic weight management later (November 2023) and for obstructive sleep apnea (December 2024). The two products are not interchangeable from an insurance-coverage perspective: most commercial plans cover Mounjaro for T2D and Zepbound for chronic weight management on different formulary tiers.
When does compounded tirzepatide make sense in T2D?
Brand Mounjaro is usually the cost-effective path for type 2 diabetes patients with commercial insurance because the FDA indication is direct and formulary coverage is broad. Compounded tirzepatide is most commonly used off-label for chronic weight management when patients lack coverage for brand Zepbound. For T2D specifically, patients should typically pursue Mounjaro coverage first.
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ MD/DO-supervised
🏥 503A & 503B pharmacies
🧪 Labs included
📍 Availability varies by state
✓ LegitScript-certified
💰 Flat-rate, dose-independent
🔁 Care360 + 1:1 fitness coaching
🍽️ Personalized nutrition plan
💳 Klarna & Afterpay accepted
$145/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ MD/DO-supervised
🏥 503A & 503B pharmacies
🧪 Labs included
📍 Availability varies by state
✓ LegitScript-certified
💰 Flat-rate, dose-independent
🔁 Care360 coaching
📱 Apple Health / Google Fit sync
$186/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month).
Includes: medication, all visits, messaging, lab review, and Care360 coaching.
Compounded tirzepatide via 503A & 503B pharmacies.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Important medical and regulatory disclosure:
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.
